NEJM: Trastuzumab Deruxtecan in metastatic HER2-mutant non-small cell lung cancer

Most non-small cell lung cancers ( NSCLC ) are caused by oncogenic variants, and targeted therapies have greatly reduced mortality in NSCLC patients in recent years
.
Mutations in the gene encoding human epidermal growth factor receptor 2 (HER2, also known as ERBB2) are closely associated with approximately 3% of non-squamous NSCLC

This study is a multicenter, international phase 2 clinical trial to evaluate the efficacy and safety of trastuzumab deruxtecan (6.
4 mg/kg) in patients with metastatic HER2-mutant NSCLC refractory to standard therapy.
security
.
The primary endpoint was objective response rate as determined by an independent central review

median progression-free survival

A total of 91 patients were recruited
.
The median follow-up was 13.

median overall survival

Drug safety was generally consistent with those reported in previous studies; 46% of patients experienced grade ≥3 drug-related adverse events, with the most common event being neutropenia (19%)
.
In addition, 26% of patients experienced drug-related interstitial lung disease, which resulted in 2 deaths

adverse event

Responses were observed in patients with different HER2 mutant subtypes, and also in patients with no detectable HER2 expression or HER2 amplification

In conclusion, trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated patients with HER2-mutant NSCLC

Original source:

Bob T.